Compare RLJ & IMCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RLJ | IMCR |
|---|---|---|
| Founded | 2011 | 2008 |
| Country | United States | United Kingdom |
| Employees | 73 | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.4B |
| IPO Year | N/A | 2016 |
| Metric | RLJ | IMCR |
|---|---|---|
| Price | $11.02 | $28.93 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 6 | 10 |
| Target Price | $7.83 | ★ $66.33 |
| AVG Volume (30 Days) | ★ 1.8M | 405.2K |
| Earning Date | 05-04-2026 | 05-07-2026 |
| Dividend Yield | ★ 7.26% | N/A |
| EPS Growth | N/A | ★ 30.39 |
| EPS | N/A | ★ 0.25 |
| Revenue | N/A | ★ $249,428,000.00 |
| Revenue This Year | $2.02 | $14.57 |
| Revenue Next Year | $2.54 | $8.21 |
| P/E Ratio | $188.67 | ★ $114.48 |
| Revenue Growth | N/A | ★ 43.05 |
| 52 Week Low | $6.54 | $27.56 |
| 52 Week High | $11.02 | $40.71 |
| Indicator | RLJ | IMCR |
|---|---|---|
| Relative Strength Index (RSI) | 83.26 | 50.21 |
| Support Level | $7.24 | $28.09 |
| Resistance Level | N/A | $31.11 |
| Average True Range (ATR) | 0.28 | 1.30 |
| MACD | 0.05 | 0.02 |
| Stochastic Oscillator | 89.78 | 56.85 |
RLJ Lodging Trust is a real estate investment trust focused on premium-branded, rooms-oriented, high-margin, focused-service, and compact full-service hotels located within the heart of demand locations. Its hotels are geographically diverse and concentrated in urban markets providing multiple demand generators from business, leisure, and other travelers. Its hotels are under the Marriott, Hilton, and Hyatt brand names. The Hotel is a single reportable segment. Its hotel segment revenues are derived from the operation of hotel properties which includes room revenue by renting hotel rooms, food and beverage revenue from the sale of food and beverages, and other revenue from parking fees, resort fees, gift shop sales, and other guest service fees.
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.